Insulet’s recurring Omnipod growth engine remains powerful, but recent quality issues have created a discounted entry point for investors willing to tolerate near-term execution risk.
Overview
Insulet is a leading diabetes technology company built around the Omnipod tubeless insulin delivery platform. Its razor-and-blade model generates recurring, high-margin revenue from disposable Pods replaced every three days. FY2025 revenue reached $2.71 billion, led by U.S. Omnipod sales and accelerating international growth. Omnipod 5’s tubeless, waterproof design, automated insulin dosing, CGM integration, and pharmacy-channel access differentiate it from traditional tubed pumps and support expanding adoption across Type 1 and insulin-intensive Type 2 diabetes patients.